Medicare advisory panel to hold meeting:
This article was originally published in Clinica
The Medicare coverage advisory committee's panel on laboratory and diagnostic services will convene next month to discuss whether the US federal health plan for the elderly and disabled should cover human tumour assay systems that detect resistance or sensitivity to chemotherapeutic agents. The Health Care Financing Administration (HCFA), which administers Medicare, currently considers such tests experimental and therefore declines to cover them. Three groups - including companies Oncotech of Irving, California and Rational Therapeutics of Long Beach, California - have asked HCFA to alter its coverage policy. The two-day event will take place on November 15 and 16 in Baltimore and will be the first public meeting of the laboratory panel.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.